title: Applications of new laboratory marker assays in neurological diagnoses - a pilot study.
abstract: 225 consecutive patients with different neurological diseases and 101 individuals as the control were examined between 2002-2004. Cystatin C, arginase-I, tau-protein and beta-amyloid were measured. Individuals with CNS inflammation had significantly lower Cystatin-C index (CSF/serum) values. There was no diagnostic significance of the Arginase-I assay in CSF was verified. The CSF tau-protein/beta-amyloid index was shown to be a sufficient efficacy for neurodegenerative disease diagnosis.
authors.affiliation: Department of Laboratory Medicine, Sternberk Hospital, Czech Republic. david.stejskal@quick.cz
authors.forename: David
authors.initials: D
authors.lastname: Stejskal
authors.forename: Jitka
authors.initials: J
authors.lastname: Vavrousková
authors.forename: Jan
authors.initials: J
authors.lastname: Mares
authors.forename: Karel
authors.initials: K
authors.lastname: Urbánek
mesh_terms: D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid; D001119:Arginase / Q000134:cerebrospinal fluid; D015415:Biomarkers / Q000134:cerebrospinal fluid; D002556:Cerebrospinal Fluid Proteins / Q000032:analysis*; D055316:Cystatin C; D015891:Cystatins / Q000134:cerebrospinal fluid; D006801:Humans; D009422:Nervous System Diseases / Q000175:diagnosis*; D016875:tau Proteins / Q000134:cerebrospinal fluid
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; C525030:CST3 protein, human; D002556:Cerebrospinal Fluid Proteins; D055316:Cystatin C; D015891:Cystatins; D016875:tau Proteins; D001119:Arginase